D.E. Shaw & Co
AVDL

D.E. Shaw & Co’s Avadel Pharmaceuticals AVDL Stock Holding History

D.E. Shaw & Co’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,600
Closed -$250K – 4535
2025
Q4 		$250K Hold
11,600
– – ﹤0.01% 4238
2025
Q3 		$177K Hold
11,600
– – ﹤0.01% 4303
2025
Q2 		$103K Hold
11,600
– – ﹤0.01% 4130
2025
Q1 		$90.8K Hold
11,600
– – ﹤0.01% 4029
2024
Q4 		$122K Buy
+11,600
New +$141K ﹤0.01% 4149

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

D.E. Shaw & Co's AVDL Position: Q1 2026 in Review

D.E. Shaw & Co sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 132,459 shares — an estimated $2.85M sold.

D.E. Shaw & Co first reported a position in AVDL in Q2 2014 and held it in 41 quarters. The position peaked at $12.6M in Q2 2023. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • D.E. Shaw & Co reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • D.E. Shaw & Co sold 132,459 Avadel Pharmaceuticals shares in Q1 2026, an estimated $2.85M.
  • D.E. Shaw & Co first reported a position in Avadel Pharmaceuticals in Q2 2014 and held it in 41 quarters.
  • D.E. Shaw & Co's Avadel Pharmaceuticals position peaked at $12.6M in Q2 2023.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.